Fig 1: ADAM10 is upregulated in experimental heart injury as well as patients with ischemic cardiomyopathy and correlates with ANP/ BNP expression.a Western blot analysis and b quantification of indicated ADAMs in heart tissue lysates of sham-operated (Sham) and LAD-ligated (MI) mice 3 days after infarction (n = 5, mean ± SEM, ns not significant, *P < 0.05, two-tailed Mann–Whitney test). Exact P-values: ADAM8, 0.150794. ADAM10, 0.015873. ADAM12, 0.150794. ADAM17, 0.690476. ADAM19, 0.690476. c Western blot analysis of ADAM10 in heart tissue lysates from patients with ischemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM) versus non-failing controls (NF) (n = 6). Pearson’s correlation of ADAM10 mRNA expression against expression of d NPPA (ANP) and e NPPB (BNP) (n = 12). Exact P-values: NPPA, <0.0001. NPPB, 0.0008. f Western blot analysis and g quantification of ADAM10 in heart tissue lysates of mice 14 days after sham-operation (Sham) and LAD-ligation (MI) (n = 6, mean ± SEM, *P = 0.011, two-tailed t test). h Immunofluorescence images and quantification of ADAM10 (A10), cardiac Troponin T (cTnT, cardiomyocytes, CM), Vimentin (Vim, fibroblasts, FB), CD31 (endothelial cells, EC) and CD45 (immune cells, IC) stained heart tissue sections of sham-operated (Sham) and LAD-ligated (MI) mice 14 days after surgery. Nuclei are stained with DAPI. Representative images are shown. Scale bar – upper panel, 20 µm. Scale bar – lower panel, 10 µm. Dotted line indicates the infarct area. n = 4 per group, mean ± SEM, ns not significant, *P < 0.05, two-tailed Mann-Whitney test. Exact P-values: CM, 0.028571. FB, 0.190476. EC, 0.714286. IC, 0.904762. i Gene expression signature of ADAM10 (A10) in indicated cell types of human hearts. Publicly available single cell sequencing data of the “Heart Cell Atlas” were analyzed. Source data are provided as a Source Data file.
Fig 2: Pathological scores of ADAM8, ADAM9, ADAM10, ADAM12 and ADAM17 expression according to the staining intensity and the percentage of cell staining. (A) Pathological scores of ADAMs in adjacent non-cancerous gastric tissues (n=15) and gastric cancer tissues (n=15). (B) Pathological scores of ADAMs in positive metastatic lymph node and negative metastatic lymph node tissues (n=15). *P<0.05, **P<0.01 vs. the corresponding control group. ADAM, disintegrin and metalloproteinase domain-containing protein.
Fig 3: Immunohistochemical analysis showing the expression of ADAM8, ADAM9, ADAM10, ADAM12 and ADAM17 in adjacent non-cancerous gastric tissues, gastric cancer tissues, positive metastatic lymph node tissues, and negative metastatic lymph node tissues. Scale bars, 50 µM. ADAM, disintegrin and metalloproteinase domain-containing protein.
Supplier Page from Proteintech Group Inc for ADAM8 antibody